Paul A. Hamlin, MD

Articles

Dr. Hamlin on the Significance of the ZUMA-I Trial

March 26th 2018

Paul A. Hamlin, MD, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the importance of the ZUMA-I trial results in the field of B-cell lymphoma.

Dr. Hamlin on Key Points of a Study on Cerdulatinib in Non-Hodgkin Lymphoma

Paul A. Hamlin, MD

November 7th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.

Dr. Hamlin on Future Combination Strategies in the MCL Landscape

Paul A. Hamlin, MD

September 6th 2017

Paul A. Hamlin, MD, medical oncologist, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses future potential combination strategies in the mantle cell lymphoma (MCL) landscape.

Dr. Hamlin on Next Steps With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

Paul A. Hamlin, MD

August 21st 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the next steps following a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Hamlin on Toxicities Associated With Ibrutinib and Buparlisib in MCL, FL, and DLBCL

Paul A. Hamlin, MD

August 10th 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the toxicities reported in a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Hamlin on Results of Cerdulatinib in CLL, Follicular Lymphoma and T-Cell Lymphoma

Paul A. Hamlin, MD

June 28th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses results of cerdulatinib in chronic lymphocytic leukemia (CLL), follicular lymphoma and T-cell lymphoma.

Dr. Hamlin on Study of Cerdulatinib in Non-Hodgkin Lymphoma

Paul A. Hamlin, MD

June 24th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Dr. Hamlin on Early Study of Ibrutinib/Buparlisib in MCL, FL, and DLBCL

Paul A. Hamlin, MD

June 12th 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).